ABLYNX (OTCMKTS:ABLYF) – Equities researchers at Jefferies Group increased their FY2017 EPS estimates for ABLYNX in a research report issued to clients and investors on Wednesday. Jefferies Group analyst P. Welford now anticipates that the company will post earnings per share of ($1.20) for the year, up from their prior estimate of ($1.29). Jefferies Group also issued estimates for ABLYNX’s FY2018 earnings at ($1.58) EPS, FY2019 earnings at ($0.71) EPS and FY2020 earnings at $0.12 EPS.
ABLYF has been the topic of several other reports. Zacks Investment Research raised shares of ABLYNX from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research note on Monday, January 8th. Bank of America started coverage on shares of ABLYNX in a research note on Friday, November 10th. They set a “buy” rating and a $26.00 price target on the stock.
WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/19/jefferies-group-brokers-increase-earnings-estimates-for-ablynx-ablyf.html.
Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.
Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.